Endo-lysosomal proteases in antigen presentation

Current Opinion in Chemical Biology

Volumn 23, Issue , 2014, Pages 8-15

  van Kasteren, Sander I ^a   Overkleeft, Herman S ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; ENDO LYSOSOMAL PROTEASE; PROTEINASE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; PEPTIDE HYDROLASE;

ACIDIFICATION; ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGENICITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; DENDRITIC CELL; ENDOSOME; ENZYME ACTIVITY; HUMAN; LYSOSOME; NONHUMAN; PHAGOSOME; PROTEIN DEGRADATION; REVIEW; ANIMAL; ENZYMOLOGY; IMMUNOLOGY; MOUSE;

ANIMALS; ANTIGEN PRESENTATION; CATHEPSINS; HUMANS; LYSOSOMES; MICE; PEPTIDE HYDROLASES;

EID: 84908086156     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2014.08.011     Document Type: Review

References (69)

1. Bone H.G., McClung M.R., Roux C., Recker R.R., Eisman J.A., Verbruggen N., Hustad C.M., DaSilva C., Santora A.C., Ince B.A. Odanacatib, a cathepsin-k inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010, 25:937-947.
2. Gauthier J.Y., Chauret N., Cromlish W., Desmarais S., Duong L.T., Falgueyret J.-P., Kimmel D.B., Lamontagne S., Leger S., LeRiche T., Li C.S., et al. The discovery of odanacatib (mk-0822), a selective inhibitor of cathepsin k. Bioorg Med Chem Lett 2008, 18:923-928.
3. Falgueyret J.-P., Desmarais S., Oballa R., Black W.C., Cromlish W., Khougaz K., Lamontagne S., Massé F., Riendeau D., Toulmond S., Percival M.D. Lysosomotropism of basic cathepsin k inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 2005, 48:7535-7543.
4. Yamashita D.S., Marquis R.W., Xie R., Nidamarthy S.D., Oh H.-J., Jeong J.U., Erhard K.F., Ward K.W., Roethke T.J., Smith B.R., Cheng H.Y., et al. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin k inhibitors. J Med Chem 2006, 49:1597-1612.
5. Asagiri M., Hirai T., Kunigami T., Kamano S., Gober H.-J., Okamoto K., Nishikawa K., Latz E., Golenbock D.T., Aoki K., Ohya K., et al. Cathepsin k-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 2008, 319:624-627.
6. Manoury B., Mazzeo D., Fugger L., Viner N., Ponsford M., Streeter H., Mazza G., Wraith D.C., Watts C. Destructive processing by asparagine endopeptidase limits presentation of a dominant t cell epitope in mbp. Nat Immunol 2002, 3:169-174.
7. Burster T., Beck A., Tolosa E., Marin-Esteban V., Rotzschke O., Falk K., Lautwein A., Reich M., Brandenburg J., Schwarz G., Wiendl H., et al. Cathepsin g, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human b lymphocytes. J Immunol 2004, 172:5495-5503.
8. Conus S., Simon H.U. Cathepsins and their involvement in immune responses. Swiss Med Wkly 2010, 140:13042.
9. Fukuda M.E., Iwadate Y., Machida T., Hiwasa T., Nimura Y., Nagai Y., Takiguchi M., Tanzawa H., Yamaura A., Seki N. Cathepsin d is a potential serum marker for poor prognosis in glioma patients. Cancer Res 2005, 65:5190-5194.
10. Khurana V., Elson-Schwab I., Fulga T.A., Sharp K.A., Loewen C.A., Mulkearns E., Tyynela J., Scherzer C.R., Feany M.B. Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLoS Genet 2010, 6:11.
11. ten Broeke T., Wubbolts R., Stoorvogel W. MHC class II antigen presentation by dendritic cells regulated through endosomal sorting. Cold Spring Harbor Perspectives in Biology 2013, 5.
12. Villadangos J.A., Bryant R.A.R., Deussing J., Driessen C., Lennon-Dumenil A.M., Riese R.J., Roth W., Saftig P., Shi G.P., Chapman H.A., Peters C., et al. Proteases involved in mhc class ii antigen presentation. Immunol Rev 1999, 172.
13. Watts C. The endosome-lysosome pathway and information generation in the immune system. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2012, 1824:14-21.
14. Manoury B. Proteases: essential actors in processing antigens and intracellular toll-like receptors. Frontiers Immunol 2013, 4:299.
15. Turk V., Stoka V., Vasiljeva O., Renko M., Sun T., Turk B., Turk D. Cysteine cathepsins: From structure, function and regulation to new frontiers. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2012, 1824:68-88.
16. Zhao L., Hua T., Crowley C., Ru H., Ni X., Shaw N., Jiao L., Ding W., Qu L., Hung L.-W., Huang W., et al. Structural analysis of asparaginyl endopeptidase reveals the activation mechanism and a reversible intermediate maturation stage. Cell Res 2014, 24:344-358.
17. Caglič D., Pungerčar J.R., Pejler G., Turk V., Turk B. Glycosaminoglycans facilitate procathepsin b activation through disruption of propeptide-mature enzyme interactions. J Biol Chem 2007, 282:33076-33085.
18. Beckman M., Freeman C., Parish C.R., Small D.H. Activation of cathepsin d by glycosaminoglycans. FEBS J 2009, 276:7343-7352.
19. Shirahama-Noda K., Yamamoto A., Sugihara K., Hashimoto N., Asano M., Nishimura M., Hara-Nishimura I. Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J Biol Chem 2003, 278:33194-33199.
20. Delamarre L., Pack M., Chang H., Mellman I., Trombetta E.S. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 2005, 307:1630-1634.
21. Savina A., Peres A., Cebrian I., Carmo N., Moita C., Hacohen N., Moita L.F., Amigorena S. The small gtpase rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in cd8(+) dendritic cells. Immunity 2009, 30:544-555.
22. Kotsias F., Hoffmann E., Amigorena S., Savina A. Reactive oxygen species production in the phagosome: impact on antigen presentation in dendritic cells. Antioxidants Redox Signal 2013, 18:714-729.
23. Nagaoka Y., Otsu K., Okada F., Sato K., Ohba Y., Kotani N., Fujii J. Specific inactivation of cysteine protease-type cathepsin by singlet oxygen generated from naphthalene endoperoxides. Biochem Biophys Res Commun 2005, 331:215-223.
24. Chapman H.A. Endosomal proteases in antigen presentation. Curr Opin Immunol 2006, 18:78-84.
25. Claesson L., Larhammar D., Rask L., Peterson P.A. Cdna clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure. Proc Nat Acad Sci USA 1983, 80:7395-7399.
26. Riberdy J.M., Newcomb J.R., Surman M.J., Barbosa J.A., Cresswell P. Hla-dr molecules from an antigen-processing mutant-cell line are associated with invariant chain peptides. Nature 1992, 360:474-477.
27. Blum J.S., Wearsch P.A., Cresswell P. Pathways of antigen processing. Annu Rev Immunol 2013, 31:443-473.
28. Blum J.S., Cresswell P. Role for intracellular proteases in the processing and transport of class-II hla antigens. Proc Natl Acad Sci USA 1988, 85:3975-3979.
29. Riese R.J., Wolf P.R., Bromme D., Natkin L.R., Villadangos J.A., Ploegh H.L., Chapman H.A. Essential role for cathepsin s in mhc class II - associated invariant chain processing and peptide loading. Immunity 1996, 4:357-366.
30. Robbins N.F., Hammond C., Denzin L.K., Pan M., Cresswell P. Trafficking of major histocompatibility complex class II molecules through intracellular compartments containing hla-dm. Hum Immunol 1996, 45:13-23.
31. Riese R.J., Mitchell R.N., Villadangos J.A., Shi G.P., Palmer J.T., Karp E.R., De Sanctis G.T., Ploegh H.L., Chapman H.A. Cathepsin s activity regulates antigen presentation and immunity. J Clin Invest 1998, 101:2351-2363.
32. Palmer J.T., Rasnick D., Klaus J.L., Bromme D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995, 38:3193-3196.
33. Nakagawa T., Roth W., Wong P., Nelson A., Farr A., Deussing J., Villadangos J.A., Ploegh H., Peters C., Rudensky A.Y. Cathepsin l: Critical role in ii degradation and cd4 t cell selection in the thymus. Science 1998, 280:450-453.
34. Tolosa E., Li W., Yasuda Y., Wienhold W., Denzin L.K., Lautwein A., Driessen C., Schnorrer P., Weber E., Stevanovic S., Kurek R., et al. Cathepsin v is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest 2003, 112:517-526.
35. Shi G.P., Bryant R.A.R., Riese R., Verhelst S., Driessen C., Li Z.Q., Bromme D., Ploegh H.L., Chapman H.A. Role for cathepsin f in invariant chain processing and major histocompatibility complex class ii peptide loading by macrophages. J Exp Med 2000, 191:1177-1185.
36. Bryant P., Ploegh H. Class ii mhc peptide loading by the professionals. Curr Opin Immunol 2004, 16:96-102.
37. Manoury B., Mazzeo D., Li D.T.N., Billson J., Loak K., Benaroch P., Watts C. Asparagine endopeptidase can initiate the removal of the mhc class ii invariant chain chaperone. Immunity 2003, 18:489-498.
38. Maehr R., Hang H.C., Mintern J.D., Kim Y.M., Cuvillier A., Nishimura M., Yamada K., Shirahama-Noda K., Hara-Nishimura I., Ploegh H.L. Asparagine endopeptidase is not essential for class ii mhc antigen presentation but is required for processing of cathepsin l in mice. J Immunol 2005, 174:7066-7074.
39. Lee-Dutra A., Wiener D.K., Sun S. Cathepsin s inhibitors: 2004-2010. Expert opinion on therapeutic patents 2011, 21:311-337.
40. Gauthier J.Y., Black W.C., Courchesne I., Cromlish W., Desmarais S., Houle R., Lamontagne S., Li C.S., Masse F., McKay D.J., Ouellet M., et al. The identification of potent, selective, and bioavailable cathepsin s inhibitors. Bioorg Med Chem Lett 2007, 17:4929-4933.
41. Samokhin A.O., Lythgo P.A., Gauthier J.Y., Percival M.D., Broemme D. Pharmacological inhibition of cathepsin s decreases atherosclerotic lesions in apoe-/- mice. J Cardiovasc Pharmacol 2010, 56:98-105.
42. Hilpert H., Mauser H., Humm R., Anselm L., Kuehne H., Hartmann G., Gruener S., Banner D.W., Benz J., Gsell B., Kuglstatter A., et al. Identification of potent and selective cathepsin s inhibitors containing different central cyclic scaffolds. J Med Chem 2013, 56:9789-9801.
43. Delamarre L., Couture R., Mellman I., Trombetta E.S. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med 2006, 203:2049-2055.
44. Colbert J.D., Matthews S.P., Miller G., Watts C. Diverse regulatory roles for lysosomal proteases in the immune response. Eur J Immunol 2009, 39:2955-2965.
45. Moss C.X., Villadangos J.A., Watts C. Destructive potential of the aspartyl protease cathepsin d in mhc class ii-restricted antigen processing. Eur J Immunol 2005, 35:3442-3451.
46. Zaidi N., Burster T., Sommandas V., Herrmann T., Boehm B.O., Driessen C., Voelter W., Kallbacher H. Natural processing sites for human cathepsin e and cathepsin d in tetanus toxin - implications for t cell epitope generation. J Immunol 1997, 159:4693-4699.
47. Zaidi N., Burster T., Sommandas V., Herrmann T., Boehm B.O., Driessen C., Voelter W., Kalbacher H. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin a. Biochem Biophys Res Commun 2007, 364:243-249.
48. Free P., Hurley C.A., Kageyama T., Chain B.M., Tabor A.B. Mannose-pepstatin conjugates as targeted inhibitors of antigen processing. Org Biomol Chem 2006, 4:1817-1830.
49. Raiber E.A., Tulone C., Zhang Y.J., Martinez-Pomares L., Steed E., Sponaas A.M., Langhorne J., Noursadeghi M., Chain B.M., Tabor A.B. Targeted delivery of antigen processing inhibitors to antigen presenting cells via mannose receptors. ACS Chem Biol 2010, 5:461-476.
50. Antoniou A.N., Blackwood S.L., Mazzeo D., Watts C. Control of antigen presentation by a single protease cleavage site. Immunity 2000, 12:391-398.
51. Manoury B., Hewitt E.W., Morrice N., Dando P.M., Barrett A.J., Watts C. An asparaginyl endopeptidase processes a microbial antigen for class ii mhc presentation. Nature 1998, 396:695-699.
52. Zhang T., Maekawa Y., Sakai T., Nakano Y., Ishii K., Hisaeda H., Dainichi T., Asao T., Katunuma N., Himeno K. Treatment with cathepsin l inhibitor potentiates t(h)2-type immune response in Leishmania major-infected balb/c mice. Int Immunol 2001, 13:975-982.
53. Matthews S.P., Werber I., Deussing J., Peters C., Reinheckel T., Watts C. Distinct protease requirements for antigen presentation in vitro and in vivo. J Immunol 2010, 184:2423-2431.
54. Hong Z., Jiang Z., Liangxi W., Guofu D., Ping L., Yongling L., Wendong P., Minghai W. Chloroquine protects mice from challenge with cpg odn and lps by decreasing proinflammatory cytokine release. Int Immunopharmacol 2004, 4:223-234.
55. Matsumoto F., Saitoh S.-i, Fukui R., Kobayashi T., Tammura N., Konnio K., Kusumoto Y., Akashi-Takamura S., Miyake K. Cathepsins are required for toll-like receptor 9 responses. Biochem Biophys Res Commun 2008, 367:693-699.
56. Ewald S.E., Lee B.L., Lau L., Wickliffe K.E., Shi G.-P., Chapman H.A., Barton G.M. The ectodomain of toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456:658-U688.
57. Park B., Brinkmann M.M., Spooner E., Lee C.C., Kim Y.-M., Ploegh H.L. Proteolytic cleavage in an endolysosomal compartment is required for activation of toll-like receptor 9. Nat Immunol 2008, 9:1407-1414.
58. Sepulveda F.E., Maschalidi S., Colisson R., Heslop L., Ghirelli C., Sakka E., Lennon-Dumenil A.-M., Amigorena S., Cabanie L., Manoury B. Critical role for asparagine endopeptidase in endocytic toll-like receptor signaling in dendritic cells. Immunity 2009, 31:737-748.
59. Ewald S.E., Engel A., Lee J., Wang M., Bogyo M., Barton G.M. Nucleic acid recognition by toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J Exp Med 2011, 208:643-651.
60. Toscano F., Estornes Y., Virard F., Garcia-Cattaneo A., Pierrot A., Vanbervliet B., Bonnin M., Ciancanelli M.J., Zhang S.-Y., Funami K., Seya T., et al. Cleaved/associated tlr3 represents the primary form of the signaling receptor. J Immunol 2013, 190:764-773.
61. Qi R., Singh D., Kao C.C. Proteolytic processing regulates toll-like receptor 3 stability and endosomal localization. J Biol Chem 2012, 287:32617-32629.
62. Hipp Madeleine M., Shepherd D., Gileadi U., Aichinger Michael C., Kessler Benedikt M., Edelmann Mariola J., Essalmani R., Seidah Nabil G., Reise Sousa C., Cerundolo V. Processing of human toll-like receptor 7 by furin-like proprotein convertases is required for its accumulation and activity in endosomes. Immunity 2013, 39:711-721.
63. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
64. El-Sukkari D., Wilson N.S., Hakansson K., Steptoe R.J., Grubb A., Shortman K., Villadangos J.A. The protease inhibitor cystatin c is differentially expressed among dendritic cell populations, but does not control antigen presentation. J Immunol 2003, 171:5003-5011.
65. Guncar G., Pungercic G., Klemencic I., Turk V., Turk D. Crystal structure of mhc class ii-associated p41 ii fragment bound to cathepsin l reveals the structural basis for differentiation between cathepsins l and s. EMBO J 1999, 18:793-803.
66. Lennon-Dumenil A.M., Roberts R.A., Valentijn K., Driessen C., Overkleeft H.S., Erickson A., Peters P.J., Bikoff E., Ploegh H.L., Wolf Bryant P. The p41 isoform of invariant chain is a chaperone for cathepsin l. EMBO J 2001, 20:4055-4064.
67. Rausch M.P., Irvine K.R., Antony P.A., Restifo N.P., Cresswell P., Hastings K.T. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. J Immunol 2010, 185:2828-2835.
68. Honey K., Duff M., Beers C., Brissette W.H., Elliot E.A., Peters C., Maric M., Cresswell P., Rudensky A. Cathepsin S regulates the expression of cathepsin L and the turnover of γ-interferon inducible lysosomal thiol reductase in B-lymphocytes. J Biol Chem 2001, 276:22573-22578.
69. van Kasteren S.I., Berlin I., Colbert J.D., Keane D., Ovaa H., Watts C. A multifunctional protease inhibitor to regulate endolysosomal function. ACS Chem Biol 2011, 6:1198-1204.